Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
George L. Bakris(University of Chicago), Michael A. Weber(SUNY Downstate Health Sciences University), Björn Dahlöf(Sahlgrenska University Hospital), Eric J. Velazquez(Duke Medical Center), Bertram Pitt(Bayer (Germany)), Kenneth Jamerson(Korea Advanced Institute of Science and Technology), Roxzana Y. Kelly(Novartis (United States)), YannTong Chiang(Novartis (United States)), Linda Staikos-Byrne(Novartis (United States)), Victor Shi(Novartis (United States)), Pantelis Sarafidis(Ippokrateio General Hospital of Thessaloniki)
Cited by 518
Related Papers
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
|Hypertension|2003|13.3k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
|Journal of the American College of Cardiology|2017|6.5k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k